Somewhat Positive Press Coverage Somewhat Unlikely to Impact AbbVie (ABBV) Share Price
Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AbbVie earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5713538734241 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Excessive Pricing And Sham Patent Litigation: The Pfizer And AbbVie Decisions (ip-watch.org)
- Mind-blowing Stocks: AbbVie Inc. (NYSE:ABBV), Heidrick & Struggles International, Inc. (NASDAQ:HSII), Omega … (thestreetpoint.com)
- Beating the Earnings Estimates or Not? AbbVie Inc. (ABBV) (nmsunews.com)
- Pfizer boosts prices of certain drugs by almost 10% (seekingalpha.com)
- How to Drive The Walt Disney Company (DIS) and AbbVie Inc. (ABBV) in Current Scenario? (nmsunews.com)
Shares of NYSE ABBV opened at $93.61 on Thursday. The company has a current ratio of 1.20, a quick ratio of 1.10 and a debt-to-equity ratio of 8.70. AbbVie has a one year low of $69.38 and a one year high of $125.86. The stock has a market capitalization of $148.55 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 0.87 and a beta of 1.61.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 15th. Shareholders of record on Friday, July 13th will be paid a $0.96 dividend. The ex-dividend date of this dividend is Thursday, July 12th. This represents a $3.84 dividend on an annualized basis and a yield of 4.10%. AbbVie’s dividend payout ratio (DPR) is currently 68.57%.
A number of equities research analysts have recently issued reports on the company. Credit Suisse Group lowered AbbVie from a “neutral” rating to a “sell” rating and cut their target price for the stock from $104.00 to $89.00 in a research report on Tuesday, May 29th. ValuEngine lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 28th. Barclays lowered their price target on AbbVie from $120.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 5th. Argus lowered their price target on AbbVie from $145.00 to $130.00 and set a “buy” rating on the stock in a report on Monday, June 11th. Finally, Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a report on Wednesday, June 27th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $105.85.
In other news, SVP Timothy J. Richmond sold 17,588 shares of the company’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $99.47, for a total transaction of $1,749,478.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Glenn F. Tilton purchased 5,400 shares of the firm’s stock in a transaction dated Wednesday, June 27th. The shares were bought at an average price of $91.90 per share, with a total value of $496,260.00. Following the purchase, the director now owns 39,735 shares in the company, valued at approximately $3,651,646.50. The disclosure for this purchase can be found here. Insiders own 0.07% of the company’s stock.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.